Characterization of treatment resistance and viral kinetics in the setting of single-versus dual-active monoclonal antibodies against SARS-CoV-2
MC Choudhary, R Deo, TH Evering… - The Journal of …, 2024 - academic.oup.com
Background Monoclonal antibodies (mAbs) represent a crucial antiviral strategy for severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, but it is unclear whether …
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, but it is unclear whether …
Characterization of treatment resistance and viral kinetics in the setting of single-versus dual-active monoclonal antibodies against SARS-CoV-2.
MC Choudhary, R Deo, TH Evering… - The Journal of …, 2024 - europepmc.org
Background Monoclonal antibodies (mAbs) represent a crucial antiviral strategy for SARS-
CoV-2 infection, but it is unclear whether combination mAbs offer a benefit over single-active …
CoV-2 infection, but it is unclear whether combination mAbs offer a benefit over single-active …
Characterization of treatment resistance and viral kinetics in the setting of single-versus dual-active monoclonal antibodies against SARS-CoV-2
MC Choudhary, R Deo, TH Evering… - The Journal of … - pubmed.ncbi.nlm.nih.gov
Background Monoclonal antibodies (mAbs) represent a crucial antiviral strategy for SARS-
CoV-2 infection, but it is unclear whether combination mAbs offer a benefit over single-active …
CoV-2 infection, but it is unclear whether combination mAbs offer a benefit over single-active …